Navigating the tumor microenvironment: mesenchymal stem cell-mediated delivery of anticancer agents

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–789. doi: 10.1002/ijc.33588.
   Web of Science ®Google Scholar
• Cheng Z, Li M, Dey R, et al. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14(1):85. doi: 10.1186/s13045-021-01096-0.
   PubMed Web of Science ®Google Scholar
• Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9(3):34. doi: 10.3390/antib9030034.
   Web of Science ®Google Scholar
• Munir M, Zaman M, Waqar MA, et al. A comprehensive review on transethosomes as a novel vesicular approach for drug delivery through transdermal route. J Liposome Res. 2023;34(1):203–218. doi: 10.1080/08982104.2023.2221354.
   PubMed Web of Science ®Google Scholar
• Gavas S, Quazi S, Karpiński TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett. 2021;16(1):173. doi: 10.1186/s11671-021-03628-6.
   PubMed Web of Science ®Google Scholar
• Waqar MA, Zaman M, Hameed H, et al. Formulation, characterization, and evaluation of β-cyclodextrin functionalized hypericin loaded nanocarriers. ACS Omega. 2023;8(41):38191–38203. doi: 10.1021/acsomega.3c04444.
   PubMed Web of Science ®Google Scholar
• Punekar SR, Velcheti V, Neel BG, et al. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19(10):637–655. doi: 10.1038/s41571-022-00671-9.
   PubMed Web of Science ®Google Scholar
• Waqar MA, Zaman M, Hameed H, et al. Ethosomes: a novel approach for the delivery of drug. IJPIHS. 2023;4(2):31–46. doi: 10.56536/ijpihs.v4i2.93.
   Google Scholar
• Huang M, Lu J-J, Ding J. Natural products in cancer therapy: past, present and future. Nat Prod Bioprospect. 2021;11(1):5–13. doi: 10.1007/s13659-020-00293-7.
   PubMed Web of Science ®Google Scholar
• Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237–253. doi: 10.1038/s41571-021-00588-9.
   PubMed Web of Science ®Google Scholar
• Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. doi: 10.1038/s41467-020-17670-y.
   PubMed Web of Science ®Google Scholar
• Ke Y, Al Aboody MS, Alturaiki W, et al. Photosynthesized gold nanoparticles from catharanthus roseus induces caspase-mediated apoptosis in cervical cancer cells (HeLa). Artif Cells Nanomed Biotechnol. 2019;47(1):1938–1946. doi: 10.1080/21691401.2019.1614017.
   PubMed Web of Science ®Google Scholar
• Cervantes-Villagrana RD, Albores-García D, Cervantes-Villagrana AR, et al. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther. 2020;5(1):99. doi: 10.1038/s41392-020-0205-z.
   PubMed Web of Science ®Google Scholar
• Ashfaq A, Riaz T, Waqar MA, et al. A comprehensive review on transdermal patches as an efficient approach for the delivery of drug. Polym Plast Technol Mater. 2024;63(8):1045–1069. doi: 10.1080/25740881.2024.2317408.
   Web of Science ®Google Scholar
• Hmadcha A, Martin-Montalvo A, Gauthier BR, et al. Therapeutic potential of mesenchymal stem cells for cancer therapy. Front Bioeng Biotechnol. 2020;8:43. doi: 10.3389/fbioe.2020.00043.
   PubMed Web of Science ®Google Scholar
• Lan T, Luo M, Wei X. Mesenchymal stem/stromal cells in cancer therapy. J Hematol Oncol. 2021;14(1):195. doi: 10.1186/s13045-021-01208-w.
   PubMed Web of Science ®Google Scholar
• Chen H-T, Liu H, Mao M-J, et al. Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy. Mol Cancer. 2019;18(1):101. doi: 10.1186/s12943-019-1030-2.
   PubMed Web of Science ®Google Scholar
• Vakhshiteh F, Atyabi F, Ostad SN. Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy. Int J Nanomed. 2019;14:2847–2859. doi: 10.2147/IJN.S200036.
   PubMed Web of Science ®Google Scholar
• Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395–417. doi: 10.1038/s41571-020-0341-y.
   PubMed Web of Science ®Google Scholar
• Waqar MA, Riaz T, Munir M, et al. Self-medication in general ailments and its potential risks. Anaesth Pain Intensive Care. 2023;27(4):579–584. doi: 10.35975/apic.v27i4.2089.
   Web of Science ®Google Scholar
• Du R, Huang C, Liu K, et al. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer. 2021;20(1):15. doi: 10.1186/s12943-020-01305-3.
   PubMed Web of Science ®Google Scholar
• Siddique S, Chow JC. Application of nanomaterials in biomedical imaging and cancer therapy. Nanomaterials. 2020;10(9):1700. doi: 10.3390/nano10091700.
   Web of Science ®Google Scholar
• Ahsan A, et al. Formulation and evaluation of miconazole lipogel for enhanced drug permeation. Pakistan J Pharm Sci. 2024;37(1):15–24.
   Web of Science ®Google Scholar
• Iqbal S, Zaman M, Waqar MA, et al. Vesicular approach of cubosomes, its components, preparation techniques, evaluation and their appraisal for targeting cancer cells. J Liposome Res. 2023;5(3):1–17. doi: 10.1080/08982104.2023.2272643.
   PubMed Web of Science ®Google Scholar
• Shariff AI, Syed S, Shelby RA, et al. Novel cancer therapies and their association with diabetes. J Mol Endocrinol. 2019;62(2):R187–R199. doi: 10.1530/JME-18-0002.
   PubMed Web of Science ®Google Scholar
• Lang F, Liu Y, Chou F-J, et al. Genotoxic therapy and resistance mechanism in gliomas. Pharmacol Ther. 2021;228:107922. doi: 10.1016/j.pharmthera.2021.107922.
   PubMed Web of Science ®Google Scholar
• Hani U, Osmani RAM, Yasmin S, et al. Novel drug delivery systems as an emerging platform for stomach cancer therapy. Pharmaceutics. 2022;14(8):1576. doi: 10.3390/pharmaceutics14081576.
   PubMed Web of Science ®Google Scholar
• Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019;95(7):936–939. doi: 10.1080/09553002.2019.1623429.
   PubMed Web of Science ®Google Scholar
• Poh HS, Lee MC, Yap SS, et al. Potential use of plasma focus radiation sources in superficial cancer therapy. Jpn J Appl Phys. 2020;59(SH):SHHB06. doi: 10.35848/1347-4065/ab7c10.
   Google Scholar
• Anderson PM, Lalla RV. Glutamine for amelioration of radiation and chemotherapy associated mucositis during cancer therapy. Nutrients. 2020;12(6):1675. doi: 10.3390/nu12061675.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Flamand Y, Weinstein GS, et al. Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311). J Clin Oncol. 2022;40(2):138–149. doi: 10.1200/JCO.21.01752.
   PubMed Web of Science ®Google Scholar
• Fu Z, Li S, Han S, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Sig Transduct Target Ther. 2022;7(1):93. doi: 10.1038/s41392-022-00947-7.
   PubMed Web of Science ®Google Scholar
• Nicolaou KC, Rigol S. The role of organic synthesis in the emergence and development of antibody–drug conjugates as targeted cancer therapies. Angew Chem Int Ed Engl. 2019;58(33):11206–11241. doi: 10.1002/anie.201903498.
   PubMed Web of Science ®Google Scholar
• Rondon A, Rouanet J, Degoul F. Radioimmunotherapy in oncology: overview of the last decade clinical trials. Cancers (Basel). 2021;13(21):5570. doi: 10.3390/cancers13215570.
   PubMed Web of Science ®Google Scholar
• Uzunhisarcikli E. Monoclonal antibodies for targeted cancer therapy. In: Pioneer and contemporary studies in health sciences. ANKEM Derg; 2023. p. 229–246. doi: 10.4161/cbt.9.8.11403.
   Google Scholar
• De Angelis ML, Francescangeli F, La Torre F, et al. Stem cell plasticity and dormancy in the development of cancer therapy resistance. Front Oncol. 2019;9:626. doi: 10.3389/fonc.2019.00626.
   PubMed Web of Science ®Google Scholar
• Thakkar S, Sharma D, Kalia K, et al. Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: a review. Acta Biomater. 2020;101:43–68. doi: 10.1016/j.actbio.2019.09.009.
   PubMed Web of Science ®Google Scholar
• Panigrahi DP, Praharaj PP, Bhol CS, et al. The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics. in. Semin Cancer Biol. 2020;66:45–58. doi: 10.1016/j.semcancer.2019.07.015.
   PubMed Web of Science ®Google Scholar
• Ginn SL, Amaya AK, Alexander IE, et al. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5):e3015. doi: 10.1002/jgm.3015.
   PubMed Web of Science ®Google Scholar
• Hossain JA, Latif MA, Ystaas LAR, et al. Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma. Neuro Oncol. 2019;21(7):890–900. doi: 10.1093/neuonc/noz060.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Shofuda T, Higuchi Y, et al. Human genomic safe harbors and the suicide gene-based safeguard system for iPSC-based cell therapy. Stem Cells Transl Med. 2019;8(7):627–638. doi: 10.1002/sctm.18-0039.
   PubMed Web of Science ®Google Scholar
• Fang H, Yan HHN, Bilardi RA, et al. Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies. Genome Med. 2022;14(1):124. doi: 10.1186/s13073-022-01131-w.
   PubMed Web of Science ®Google Scholar
• Cao Z, Wu Y, Yu L, et al. Exosomal miR-335 derived from mature dendritic cells enhanced mesenchymal stem cell-mediated bone regeneration of bone defects in athymic rats. Mol Med. 2021;27(1):20. doi: 10.1186/s10020-021-00268-5.
   PubMed Web of Science ®Google Scholar
• Li Z, Yu X-F, Chu PK. Recent advances in cell-mediated nanomaterial delivery systems for photothermal therapy. J Mater Chem B. 2018;6(9):1296–1311. doi: 10.1039/c7tb03166a.
   PubMed Web of Science ®Google Scholar
• Xie M. Mesenchymal stem cells mediated drug delivery in tumor-targeted therapy. CDD. 2021;18(7):876–891. doi: 10.2174/18755704MTA56Mjkuz.
   PubMed Web of Science ®Google Scholar
• Carvalho AÉSilva, Sousa MRR, Alencar-Silva T, et al. Mesenchymal stem cells immunomodulation: the road to IFN-γ licensing and the path ahead. Cytokine Growth Factor Rev. 2019;47:32–42. doi: 10.1016/j.cytogfr.2019.05.006.
   PubMed Web of Science ®Google Scholar
• Munoz-Perez E, Gonzalez-Pujana A, Igartua M, et al. Mesenchymal stromal cell secretome for the treatment of immune-mediated inflammatory diseases: latest trends in isolation, content optimization and delivery avenues. Pharmaceutics. 2021;13(11):1802. doi: 10.3390/pharmaceutics13111802.
   PubMed Web of Science ®Google Scholar
• Ceruso A, Gonzalez-Pujana A, Igartua M, et al. Latest advances to enhance the therapeutic potential of mesenchymal stromal cells for the treatment of immune-mediated diseases. Drug Deliv Transl Res. 2021;11(2):498–514. doi: 10.1007/s13346-021-00934-5.
   PubMed Web of Science ®Google Scholar
• Baek G, Choi H, Kim Y, et al. Mesenchymal stem cell-derived extracellular vesicles as therapeutics and as a drug delivery platform. Stem Cells Transl Med. 2019;8(9):880–886. doi: 10.1002/sctm.18-0226.
   PubMed Web of Science ®Google Scholar
• Yoon A-R, Hong J, Li Y, et al. Mesenchymal stem cell–mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma. Cancer Res. 2019;79(17):4503–4514. doi: 10.1158/0008-5472.CAN-18-3900.
   PubMed Web of Science ®Google Scholar
• Wang L-T, Liu K-J, Sytwu H-K, et al. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Transl Med. 2021;10(9):1288–1303. doi: 10.1002/sctm.21-0021.
   PubMed Web of Science ®Google Scholar
• Yoon J, Lee SK, Park A, et al. Exosome from IFN-γ-primed induced pluripotent stem cell-derived mesenchymal stem cells improved skin inflammation and barrier function. Int J Mol Sci. 2023;24(14):11635. doi: 10.3390/ijms241411635.
   PubMed Web of Science ®Google Scholar
• Chulpanova DS, Kitaeva KV, Tazetdinova LG, et al. Application of mesenchymal stem cells for therapeutic agent delivery in anti-tumor treatment. Front Pharmacol. 2018;9:259. doi: 10.3389/fphar.2018.00259.
   PubMed Web of Science ®Google Scholar
• Kuşoğlu A, Avcı ÇB. Cancer stem cells: a brief review of the current status. Gene. 2019;681:80–85. doi: 10.1016/j.gene.2018.09.052.
   PubMed Web of Science ®Google Scholar
• Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8. doi: 10.1038/s41392-020-0110-5.
   PubMed Web of Science ®Google Scholar
• Clarke MF. Clinical and therapeutic implications of cancer stem cells. N Engl J Med. 2019;380(23):2237–2245. doi: 10.1056/NEJMra1804280.
   PubMed Web of Science ®Google Scholar
• Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother. 2021;137:111285. doi: 10.1016/j.biopha.2021.111285.
   PubMed Web of Science ®Google Scholar
• Merle P, Blanc J-F, Phelip J-M, et al. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(6):454–465. doi: 10.1016/S2468-1253(19)30040-8.
   PubMed Web of Science ®Google Scholar
• Alsubait SA, Al Ajlan R, Mitwalli H, et al. Cytotoxicity of different concentrations of three root canal sealers on human mesenchymal stem cells. Biomolecules. 2018;8(3):68. doi: 10.3390/biom8030068.
   PubMed Web of Science ®Google Scholar
• Baxter-Holland M, Dass CR. Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use. J Pharm Pharmacol. 2018;70(3):320–327. doi: 10.1111/jphp.12869.
   PubMed Web of Science ®Google Scholar
• Hass R. Role of MSC in the tumor microenvironment. Cancers (Basel). 2020;12(8):2107. doi: 10.3390/cancers12082107.
   PubMed Web of Science ®Google Scholar
• Jovic D, Yu Y, Wang D, et al. A brief overview of global trends in MSC-based cell therapy. Stem Cell Rev Rep. 2022;18(5):1525–1545. doi: 10.1007/s12015-022-10369-1.
   PubMed Web of Science ®Google Scholar
• Rossignoli F, Grisendi G, Spano C, et al. Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy. Cancer Gene Ther. 2019;26(1-2):11–16. doi: 10.1038/s41417-018-0034-1.
   PubMed Web of Science ®Google Scholar
• Silva LHA, Antunes MA, Dos Santos CC, et al. Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases. Stem Cell Res Ther. 2018;9(1):45. doi: 10.1186/s13287-018-0802-8.
   PubMed Web of Science ®Google Scholar
• Damasceno PKF, de Santana TA, Santos GC, et al. Genetic engineering as a strategy to improve the therapeutic efficacy of mesenchymal stem/stromal cells in regenerative medicine. Front Cell Dev Biol. 2020;8:737. doi: 10.3389/fcell.2020.00737.
   PubMed Web of Science ®Google Scholar
• Ocansey DKW, Pei B, Yan Y, et al. Improved therapeutics of modified mesenchymal stem cells: an update. J Transl Med. 2020;18(1):42. doi: 10.1186/s12967-020-02234-x.
   PubMed Web of Science ®Google Scholar
• Ma S, Xie N, Li W, et al. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21(2):216–225. doi: 10.1038/cdd.2013.158.
   PubMed Web of Science ®Google Scholar
• Meirelles LdS, Fontes AM, Covas DT, et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20(5–6):419–427. doi: 10.1016/j.cytogfr.2009.10.002.
   PubMed Web of Science ®Google Scholar
• Stewart MC, Stewart AA. Mesenchymal stem cells: characteristics, sources, and mechanisms of action. Vet Clin equine Pract. 2011;27(2):243–261.
   PubMed Web of Science ®Google Scholar
• Gnecchi M, et al. Paracrine mechanisms of mesenchymal stem cells in tissue repair. Mesenchymal stem cells: methods and protocols; 2016. p. 123–146. doi: 10.1007/978-1-4939-3584-0_7.
   Google Scholar
• Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol. 2011;6(1):457–478. doi: 10.1146/annurev-pathol-011110-130230.
   PubMedGoogle Scholar
• Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493–507. doi: 10.1038/s41581-018-0023-5.
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20(1):14–20. doi: 10.1038/mt.2011.211.
   PubMed Web of Science ®Google Scholar
• Newman RE, Yoo D, LeRoux MA, et al. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets. 2009;8(2):110–123. doi: 10.2174/187152809788462635.
   PubMedGoogle Scholar
• Rubio D, Garcia S, De la Cueva T, et al. Human mesenchymal stem cell transformation is associated with a mesenchymal–epithelial transition. Exp Cell Res. 2008;314(4):691–698. doi: 10.1016/j.yexcr.2007.11.017.
   PubMed Web of Science ®Google Scholar
• Liu H, Li D, Zhang Y, et al. Inflammation, mesenchymal stem cells and bone regeneration. Histochem Cell Biol. 2018;149(4):393–404. doi: 10.1007/s00418-018-1643-3.
   PubMed Web of Science ®Google Scholar
• Heidari HR, et al. Mesenchymal stem cells cause telomere length reduction of molt-4 cells via caspase-3, BAD and P53 apoptotic pathway. Int J Mol Cell Med. 2021;10(2):113.
   PubMed Web of Science ®Google Scholar
• Baharaghdam S, et al. Effects of hypoxia on biology of human leukemia T-cell line (MOLT-4 cells) co-cultured with bone marrow mesenchymal stem cells. Avicenna J Med Biotechnol. 2018;10(2):62.
   PubMedGoogle Scholar
• Robb KP, Fitzgerald JC, Barry F, et al. Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. Cytotherapy. 2019;21(3):289–306. doi: 10.1016/j.jcyt.2018.10.014.
   PubMed Web of Science ®Google Scholar
• Zhao S, Huang M, Yan L, et al. Exosomes derived from baicalin-pretreated mesenchymal stem cells alleviate hepatocyte ferroptosis after acute liver injury via the Keap1-NRF2 pathway. Oxid Med Cell Longev. 2022;2022:8287227–8287218. doi: 10.1155/2022/8287227.
   PubMed Web of Science ®Google Scholar
• Tang T-T, Wang B, Lv L-L, et al. Extracellular vesicles for renal therapeutics: state of the art and future perspective. J Control Release. 2022;349:32–50. doi: 10.1016/j.jconrel.2022.06.049.
   PubMed Web of Science ®Google Scholar
• Hao Y, Miao J, Liu W, et al. Mesenchymal stem cell-derived exosomes carry MicroRNA-125a to protect against diabetic nephropathy by targeting histone deacetylase 1 and downregulating endothelin-1. Diabetes Metab Syndr Obes. 2021;14:1405–1418. doi: 10.2147/DMSO.S286191.
   PubMed Web of Science ®Google Scholar
• Guo S, Perets N, Betzer O, et al. Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and tensin homolog siRNA repairs complete spinal cord injury. ACS Nano. 2019;13(9):10015–10028. doi: 10.1021/acsnano.9b01892.
   PubMed Web of Science ®Google Scholar
• Andrzejewska A, Lukomska B, Janowski M. Concise review: mesenchymal stem cells: from roots to boost. Stem Cells. 2019;37(7):855–864. doi: 10.1002/stem.3016.
   PubMed Web of Science ®Google Scholar
• Layek B, Sadhukha T, Panyam J, et al. Nano-engineered mesenchymal stem cells increase therapeutic efficacy of anticancer drug through true active tumor targeting. Mol Cancer Ther. 2018;17(6):1196–1206. doi: 10.1158/1535-7163.MCT-17-0682.
   PubMed Web of Science ®Google Scholar
• Andrée L, Barata D, Sutthavas P, et al. Guiding mesenchymal stem cell differentiation using mesoporous silica nanoparticle-based films. Acta Biomater. 2019;96:557–567. doi: 10.1016/j.actbio.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Yang N, Ding Y, Zhang Y, et al. Surface functionalization of polymeric nanoparticles with umbilical cord-derived mesenchymal stem cell membrane for tumor-targeted therapy. ACS Appl Mater Interfaces. 2018;10(27):22963–22973. doi: 10.1021/acsami.8b05363.
   PubMed Web of Science ®Google Scholar
• Ping Y-F, Yao X-h, Jiang J-y, et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol. 2011;224(3):344–354. doi: 10.1002/path.2908.
   PubMed Web of Science ®Google Scholar
• Myszczyszyn A, Czarnecka AM, Matak D, et al. The role of hypoxia and cancer stem cells in renal cell carcinoma pathogenesis. Stem Cell Rev Rep. 2015;11(6):919–943. doi: 10.1007/s12015-015-9611-y.
   PubMed Web of Science ®Google Scholar
• Yin T, Wang G, He S, et al. Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells. Cell Immunol. 2016;300:41–45. doi: 10.1016/j.cellimm.2015.11.009.
   PubMed Web of Science ®Google Scholar
• Jamal SME, Alamodi A, Wahl RU, et al. Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways. Oncogene. 2020;39(32):5468–5478. doi: 10.1038/s41388-020-1373-6.
   PubMed Web of Science ®Google Scholar
• Chen D, Wang C-Y. Targeting cancer stem cells in squamous cell carcinoma. Precis Clin Med. 2019;2(3):152–165. doi: 10.1093/pcmedi/pbz016.
   PubMedGoogle Scholar
• Krantz SB, Shields MA, Dangi-Garimella S, et al. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res. 2012;173(1):105–112. doi: 10.1016/j.jss.2011.09.020.
   PubMed Web of Science ®Google Scholar
• Kim BR, Van de Laar E, Cabanero M, et al. SOX2 and PI3K cooperate to induce and stabilize a squamous-committed stem cell injury state during lung squamous cell carcinoma pathogenesis. PLoS Biol. 2016;14(11):e1002581. doi: 10.1371/journal.pbio.1002581.
   PubMed Web of Science ®Google Scholar
• Chopra N, Choudhury S, Bhargava S, et al. Potentials of “stem cell-therapy” in pancreatic cancer: an update. Pancreatology. 2019;19(8):1034–1042. doi: 10.1016/j.pan.2019.09.016.
   PubMed Web of Science ®Google Scholar
• Scioli MG, Artuso S, D’Angelo C, et al. Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth. PLoS One. 2018;13(9):e0203426. doi: 10.1371/journal.pone.0203426.
   PubMed Web of Science ®Google Scholar
• Wang X, Gao J, Ouyang X, et al. Mesenchymal stem cells loaded with paclitaxel-poly (lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy. Int J Nanomed. 2018;13:5231–5248. doi: 10.2147/IJN.S167142.
   PubMed Web of Science ®Google Scholar
• Wu H-H, Zhou Y, Tabata Y, et al. Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J Control Release. 2019;294:102–113. doi: 10.1016/j.jconrel.2018.12.019.
   PubMed Web of Science ®Google Scholar
• Liu R, Colby AH, Gilmore D, et al. Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma. Biomaterials. 2016;102:175–186. doi: 10.1016/j.biomaterials.2016.06.031.
   PubMed Web of Science ®Google Scholar
• Ham SY, Kwon T, Bak Y, et al. Mucin 1-mediated chemo-resistance in lung cancer cells. Oncogenesis. 2016;5(1):e185-e185–e185. doi: 10.1038/oncsis.2015.47.
   Google Scholar
• Vathipadiekal V, Saxena D, Mok SC, et al. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One. 2012;7(1):e29079. doi: 10.1371/journal.pone.0029079.
   PubMed Web of Science ®Google Scholar
• Akbulut H, Tang Y, Akbulut KG, et al. Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of lewis lung cancer cells. Gene Ther. 2010;17(11):1333–1340. doi: 10.1038/gt.2010.93.
   PubMed Web of Science ®Google Scholar
• Shen Y, Li Y, Ma X, et al. Connexin 43 SUMOylation improves gap junction functions between liver cancer stem cells and enhances their sensitivity to HSVtk/GCV. Int J Oncol. 2018;52(3):872–880. doi: 10.3892/ijo.2018.4263.
   PubMed Web of Science ®Google Scholar
• Fujii H, et al. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol. 2009;34(5):1381–1386.
   PubMed Web of Science ®Google Scholar
• Zheng J, Lu Y, Lin Y, et al. Epitranscriptomic modifications in mesenchymal stem cell differentiation: advances, mechanistic insights, and beyond. Cell Death Differ. 2024;31(1):9–27. doi: 10.1038/s41418-023-01238-6.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Xu RH, Dai Y. Nanoghosts: harnessing mesenchymal stem cell membrane for construction of drug delivery platforms via optimized biomimetics. Small. 2024;20(1):e2304824. doi: 10.1002/smll.202304824.
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang Y, Peng Q, et al. Regulating pyroptosis by mesenchymal stem cells and extracellular vesicles: a promising strategy to alleviate intervertebral disc degeneration. Biomed Pharmacother. 2024;170:116001. doi: 10.1016/j.biopha.2023.116001.
   PubMed Web of Science ®Google Scholar
• Gou Y, Huang Y, Luo W, et al. Adipose-derived mesenchymal stem cells (MSCs) are a superior cell source for bone tissue engineering. Bioact Mater. 2024;34:51–63. doi: 10.1016/j.bioactmat.2023.12.003.
   PubMed Web of Science ®Google Scholar
• Cao C, Maska B, Malik MA, et al. Immunomodulatory differences between mesenchymal stem cells from different oral tissues. Heliyon. 2024;10(1):e23317. doi: 10.1016/j.heliyon.2023.e23317.
   PubMed Web of Science ®Google Scholar
• Soleimani A, Oraee Yazdani S, Pedram M, et al. Intrathecal injection of human placental mesenchymal stem cells derived exosomes significantly improves functional recovery in spinal cord injured rats. Mol Biol Rep. 2024;51(1):193. doi: 10.1007/s11033-023-08972-7.
   PubMed Web of Science ®Google Scholar
• Zayed HM, Kheir El Din NH, Abu-Seida AM, et al. Gingival-derived mesenchymal stem cell therapy regenerated the radiated salivary glands: functional and histological evidence in murine model. Stem Cell Res Ther. 2024;15(1):46. doi: 10.1186/s13287-024-03659-7.
   PubMed Web of Science ®Google Scholar